ClinicalTrials.gg
CompletedNCT03694574Updated Oct 9, 2018

Emotion Regulation in Trait Schizotypy

An interventional study of instruction to suppress and instruction to reappraise in Trait Schizotypy, sponsored by Danube University Krems. Completed. Open to participants aged 18 Years to 58 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by Danube University Krems · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Mar 2016, registered Oct 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 58 Years
Sex
All
01

Study summary

Our aim is to compare state anger and state emotion regulation strategies in healthy individuals with high trait schizotypy and to look at differences of induced anger, negative emotions, decrease of positive emotions and aggressive behaviour after anger induction. Our further aim is to compare conditions where an instruction to suppress or reappraise emotions is given with a control condition with no instruction.

02

Conditions studied

  • Trait Schizotypy
03

In context

Lead sponsor

Danube University Krems is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age between 18 and 58 years,
  • good command of German language

Exclusion criteria

Exclusion Criteria:

  • present or past psychiatric or neurological illness,
  • ongoing treatment with psychiatric drugs,
  • constant consume of heroin or hallucinogenic drugs,
  • alcohol dependence,
  • cannabis consume two weeks before testing.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Other
    Low schizotypy

    Schizotypy score \< 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, \& Jahn, 1997)

    Behavioral: instruction to suppress · Behavioral: instruction to reappraise · Behavioral: control

  • Other
    High schizotypy

    Schizotypy score ≥ 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, \& Jahn, 1997)

    Behavioral: instruction to suppress · Behavioral: instruction to reappraise · Behavioral: control

Interventions

  • Behavioralinstruction to suppress

    "It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated." (Szasz, Szentagothai, \& Hoffmann, 2011)

  • Behavioralinstruction to reappraise

    "It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning." (Szasz et al., 2011)

  • Behavioralcontrol

    No instruction

06

What researchers measure

Primary outcomes

  1. state anger

    measured by the German version of State-Trait Anger Expression Inventory (Schwenkmetzger, Hodapp, \& Spielberger, 1992)

    Time frame: 3 minutes

  2. state negative emotions

    measured by the German Version of Positive and Negative Affect Schedule (Krohne, Egloff, Kohlmann, \& Tausch, 1996)

    Time frame: 3 minutes

  3. state positive emotions

    measured by the German Version of Positive and Negative Affect Schedule (Krohne, Egloff, Kohlmann, \& Tausch, 1996)

    Time frame: 3 minutes

  4. aggressive behavior

    measured by the amount of chili measured by the Hot Sauce Paradigm (Lieberman, Solomon, Greenberg, \& McGregor, 1999)

    Time frame: 3 minutes

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Klein, C., Andresen, B., & Jahn, T. (1997). Erfassung der schizotypen Persönlichkeit nach DSM-III-R: Psychometrische Eigenschaften einer autorisierten deutschsprachigen Übersetzung des
  • Krohne, H. W., Egloff, B., Kohlmann, C. W., & Tausch, A. (1996). Untersuchung mit einer deutschen Form der Positive and Negative Affect Schedule (PANAS). Diagnostica, 42, 139-156.
  • Lieberman, J. D., Solomon, S., Greenberg, J. & McGregor, H. A. (1999). A hot new way to measure aggression: hot sauce allocation, Aggressive Behavior, 25, 331-348
  • Schwenkmetzger, P., Hodapp, V., & Spielberger, C. D. (1992). Das State-Trait-Ärgerausdrucks-Inventar (STAXI). Bern: Huber.
  • Szasz PL, Szentagotai A, Hofmann SG. The effect of emotion regulation strategies on anger. Behav Res Ther. 2011 Feb;49(2):114-9. doi: 10.1016/j.brat.2010.11.011. Epub 2010 Dec 9. PubMed 21185551 ↗

Individual participant data

Plan to share: Undecided — Interested researchers can request the data from the primary investigator (krisztina.kocsis-bogar@donau-uni.ac.at). Please give a short description of the study including an explanation about how you are going to use the data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in May 2017, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2018
First posted
Oct 3, 2018
StartActual
Mar 1, 2016
Primary completionActual
May 31, 2017
CompletionActual
Sep 30, 2017
Last update
Oct 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03694574
Lead sponsor
Danube University Krems
Collaborators
University of Vienna
Responsible party
Krisztina Kocsis-Bogar (academic staff, Danube University Krems) — Principal investigator
First posted
Oct 3, 2018
Start date
Mar 1, 2016
Primary completion
May 31, 2017
Completion
Sep 30, 2017
Last update
Oct 9, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion